GROWTH FACTOR MAY LINK
TWO PARALYZING DISORDERS
TUCSON, Ariz., March 4, 2004 — Vascular endothelial growth factor,
otherwise known as VEGF, may be a surprising link underlying amyotrophic
lateral sclerosis (ALS) and spinal-bulbar
muscular atrophy (SBMA), the Muscular Dystrophy Association announced
today.
ALS, also known as Lou Gehrig’s disease, is a rapidly progressive
disease in which the motor neurons — nerve cells that control
muscles — are lost, with resulting paralysis of all voluntary
muscle. MDA-supported researchers found last summer that variations
in the VEGF gene are apparent risk factors for the disease.
In about 90 percent of cases of ALS, there is no family history, and
the cause is unknown.
SBMA, also known as Kennedy’s disease, is a less rapidly progressive
but similarly paralyzing disease. It was found by MDA-supported researchers
in 1991 to be caused by a flaw in the androgen receptor gene on the
X chromosome.
In today’s issue of the journal Neuron, MDA-supported investigators
Albert La Spada of the University of Washington in Seattle and Lisa
Ellerby of the Buck Institute in Novato, Calif., report on a mechanism
by which the flawed androgen receptor may cause SBMA.
They found that the abnormal androgen receptor, itself a protein, sticks
to and interferes with a binding protein, and that this binding protein
is needed for the manufacture of VEGF. The result, a deficiency of VEGF,
is likely responsible for the loss of motor neurons.
To conduct their experiments, they developed mice with exactly the same
type of genetic defect for SBMA that’s found in humans. Research
suggests experiments with these mice and ALS-affected mice are needed
to see whether delivering VEGF to the nervous system can save motor
neurons.
“We cannot exclude involvement of other factors or genes at this
time,” La Spada said, “and further work is ongoing to determine
if VEGF delivery to our mice will be sufficient to prevent and/or reverse
their disease.”
But, he continued, “One distinct possibility is that all motor
neuron diseases share interruption of the VEGF axis as part of their
pathogenesis, an intriguing notion that, if true, could have dramatic
implications for treatment.”
MDA is a voluntary health agency working to defeat more than 40 neuromuscular
diseases through programs of worldwide research, comprehensive services,
and far-reaching professional and public health education. For more
information about MDA, call (800) 572-1212 or visit www.mda.org.
|